- Three year data from the Phase 3 GEMINI 1 and GEMINI 2 studies evaluating ViiV Healthcare's two-drug regimen of dolutegravir and lamivudine (branded as Dovato) showed it to be non-inferior (no worse than) to the three-drug regimen of dolutegravir plus two nucleoside reverse transcriptase inhibitors, tenofovir disoproxil fumarate/emtricitabine (TDF/FTC), in treatment-naïve adults with HIV-1. The results were presented at HIV Glasgow.
- On the treatment resistance front, only 1.7% (n=12/716) of patients experienced confirmed virologic withdrawal compared to 1.3% (n=9/717) in the dolutegravir + TDF/FTC group. None developed treatment-emergent resistance mutations.
- The FDA approved Dovato in April 2019 for treatment-naïve adults with HIV-1.
- ViiV Healthcare is the HIV-focused joint venture between GlaxoSmithKline (NYSE:GSK) (+1%), Pfizer (NYSE:PFE) (+1%) and Shionogi (OTCPK:SGIOY).
- https://seekingalpha.com/news/3619720-viiv-hiv-doublet-therapy-on-par-triplet-in-previously-untreated-adults
Monday, October 5, 2020
ViiV HIV doublet therapy on par with triplet in previously untreated adults
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.